Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.73 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30644240 | 1.00 | PDGFRB (0.73) | PDGFRBPDGFRANR4A2ESR2ADORA3 | |
| SCHEMBL26613541 | 0.86 | PDGFRB (0.54) | PDGFRBPDGFRAADORA3ADORA1MAP4K4 | |
| SCHEMBL31060338 | 0.84 | PDGFRB (1.00) | PDGFRBPDGFRANR4A2ESR2MAP4K4 | |
| SCHEMBL28191718 | 0.83 | ESR2 (0.59) | PDGFRBPDGFRAESR2MAP4K4AXL | |
| SCHEMBL29060493 | 0.80 | PDGFRB (0.66) | PDGFRBPDGFRAESR2MAP4K4CYP2A6 | |
| SCHEMBL29375315 | 0.80 | PDGFRB (0.66) | PDGFRBPDGFRAESR2MAP4K4CYP2A6 | |
| SCHEMBL708999 | 0.79 | PDGFRB (0.75) | PDGFRBPDGFRAMAP4K4AXLCDK8 | |
| SCHEMBL20759765 | 0.79 | PSMB5 (0.63) | PDGFRBPDGFRAESR2ADORA3ADORA1 | |
| SCHEMBL20741503 | 0.79 | TLR9 (0.58) | PDGFRBPDGFRAESR2ADORA3AXL | |
| SCHEMBL26560544 | 0.79 | PDGFRB (0.64) | PDGFRBPDGFRAESR2MAP4K4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2026-03-26 | — | — | US | disclosed |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4545079-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | Toray Industries, Inc. (JP) | 2025-04-30 | — | — | EP | disclosed |
| CN-119403554-A | Therapeutic or prophylactic agent for amyotrophic lateral sclerosis | 东丽株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-20240116903-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2024-04-11 | — | — | US | disclosed |
| WO-2023249105-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR DRUG-INDUCED MYOCARDIAL DISORDERS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249106-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249107-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR PERIPHERAL NERVE DISORDER | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| CN-117003695-A | Preparation method of 2, 3-disubstituted quinoline derivative | 广东工业大学 | 2023-11-07 | — | — | CN | disclosed |
| EP-4269392-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | Toray Industries, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269392-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | Toray Industries, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116648245-A | Tetrahydroquinoline derivative and medical application thereof | 东丽株式会社 | 2023-08-25 | — | — | CN | disclosed |
| WO-2022138888-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | 東レ株式会社 | 2022-06-30 | — | — | WO | disclosed |
| CN-114031552-A | Method for synthesizing substituted quinoline derivative from aromatic aldehyde and aromatic amine participated in DMSO | 长沙资材科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20060074105-A1 | Substituted quinoline and quinazoline inhibitors of quinone reductase 2 | SERENEX, INC. (US) | 2006-04-06 | — | — | US | disclosed |
| WO-2006034235-A2 | SUBSTITUTED QUINOLINE AND QUINAZOLINE INHIBITORS OF QUINONE REDUCTASE 2 | SERENEX, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074105-A1 | Substituted quinoline and quinazoline inhibitors of quinone reductase 2 | NQO2, QTRT1, QTRT2 | PDGFRB 4772/4885PDGFRA 4728/4885NR4A2 1356/4885 |
| US-20240116903-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | AIFM2, TXNRD2, NFE2L2 | PDGFRB 3381/4885PDGFRA 3877/4885NR4A2 1226/4885 |
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | AIFM2, GPX1, SOD1 | PDGFRB 3258/4885PDGFRA 3519/4885NR4A2 1685/4885 |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | AIFM2, GPX1, GPX4 | PDGFRB 2960/4885PDGFRA 3340/4885NR4A2 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.